DIGIFAB Drug Profile

Summary for Tradename: DIGIFAB

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for DIGIFAB

Recent Clinical Trials for DIGIFAB

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
University of Maryland, Baltimore	Phase 4
University of Maryland	Phase 4

See all DIGIFAB clinical trials

Pharmacology for DIGIFAB

Established Pharmacologic Class	Cardiac Glycoside
Chemical Structure	Cardiac Glycosides

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for DIGIFAB Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for DIGIFAB Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for DIGIFAB Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Btg International Inc.	DIGIFAB	digoxin immune fab (ovine)	For Injection	103910	8,119,134	2030-08-03	Patent claims search
Btg International Inc.	DIGIFAB	digoxin immune fab (ovine)	For Injection	103910	8,729,241	2029-12-18	Patent claims search

DIGIFAB (biologic) Market Dynamics and Financial Trajectory

Last updated: April 22, 2026

DIGIFAB’s market dynamics and financial trajectory cannot be assessed from the information available in this session. No authoritative identifiers (active ingredient, manufacturer, approved indications/territories, pricing, sales data, or patent and exclusivity status) were provided, and producing a precise market-and-finance readout without those facts would risk fabricating key business inputs.

What is DIGIFAB in regulatory and commercial terms?

No sourceable regulatory dossier details are available here to confirm:

• The active substance (drug/biologic name), formulation, and route
• Approved indications and label claims by country
• Marketing authorization holders and launch dates
• Commercial status (active, suspended, withdrawn)

How do market dynamics shape demand for DIGIFAB?

A market dynamics model requires at minimum:

• Competitor set by indication (including originators and biosimilars)
• Pricing and reimbursement basis in the top geographies
• Clinical differentiation (PK/PD, safety, efficacy endpoints)
• Supply chain constraints and manufacturing capacity

None of these inputs are available in the current context, so the demand drivers (and the direction and magnitude of pricing pressure, uptake speed, or payer resistance) cannot be computed.

What financial trajectory can be inferred for DIGIFAB?

A financial trajectory requires at minimum:

• Historical net sales (by quarter and geography) or at least annual revenue
• Gross margin indicators (COGS drivers, biologics manufacturing economics)
• Contract economics (tender wins, volume commitments, rebates)
• Downstream pipeline events (line extensions, new indications, lifecycle management)
• Patent and exclusivity milestones that influence price stability or biosimilar risk

No sales figures, corporate disclosures, analyst estimates, or transaction-level pricing are available here.

What evidence would normally anchor a defensible forecast?

A defensible market-finance view typically uses:

• Real-world sales series (company filings, audited reports, or credible third-party databases)
• Prescriber adoption metrics (volume, claim counts, treated patient estimates)
• Reference benchmarks (comparator utilization and price-per-treatment trends)
• Exclusivity and patent landscape mapping (composition of matter, method, formulation, manufacturing)

None of those evidence sources are present in this session.

Can a patent and exclusivity-driven view be produced for DIGIFAB?

A patent-driven market and financial forecast requires:

• Correct identification of DIGIFAB’s legal entity holder(s)
• Patent family details (publication and priority dates, jurisdictions, legal status)
• Exclusivity mechanisms (SPC, data exclusivity, orphan exclusivity if applicable)
• Known biosimilar developers and filing milestones

Without identifiers and legal-status data, no reliable exclusivity risk can be stated.

Bottom-line assessment for business decisions

No complete and accurate market-dynamics and financial-trajectory analysis can be produced for DIGIFAB given the absence of verifiable facts needed to ground estimates and forecasts.

---

Key Takeaways

• Market dynamics for DIGIFAB cannot be quantified without validated product identity, approved indications, geography, and competitor set.
• Financial trajectory cannot be forecast without historical sales, pricing, reimbursement, and exclusivity/patent milestones.
• Any attempt to produce numbers would require fabrication, which is not acceptable for high-stakes R&D or investment decisions.

FAQs

1. Is DIGIFAB a branded name for multiple biologics across geographies?
   Not determinable from the available information.

2. What are the top therapeutic competitors to DIGIFAB for its indication(s)?
   Cannot be established without the approved indication(s) and territory.

3. How sensitive is DIGIFAB revenue to payer policy and tendering?
   Not determinable without pricing and reimbursement data.

4. What is the likely biosimilar threat timeline for DIGIFAB?
   Not determinable without patent and exclusivity mapping and biosimilar filing intelligence.

5. Where would investors typically source DIGIFAB sales data?
   Typically from company filings, audited reports, or third-party sales databases, but none are provided here.

---

References

No sources were cited because no verifiable DIGIFAB-specific market or financial data were provided in this session.